Teva Halts Phase III Trial of Fremanezumab in Chronic Cluster Headaches

Teva Pharmaceutical Industries said today it will halt a Phase III trial of fremanezumab (TEV-48125) for chronic cluster headaches, after concluding that the study is unlikely to meet its primary endpoint of a reduced number of headaches.Teva said it is ending the chronic cluster headache trial ( NCT02964338 ) after a prespecified futility analysis showed that fremanezumab was unlikely to meet the study’s primary endpoint of mean change from baseline in the monthly average number of cluste